glp 1 agonists for type 2 diabetes GLP-1-based therapies diabetes: from single, dual and triple to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome VisualAbstract: Glucagon-like peptide 1 receptor
Description
10.1007/s00592-018-1271-3 173 ShahZ.KampfrathT.DeiuliisJ
Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: post hoc analyses from DECLARE-TIMI 58
[51] Vickers, S
European Medicines Agency .Summary of product characteristics: OZEMPIC (semaglutide)
[cited 2025 Mar 6]
These features make GLP-1 RAs an advantageous alternative to rapid-acting insulin for patients inadequately controlled on a long-acting basal insulin
